Wall Street is positive on Nektar Therapeutics (NKTR). On average, analysts give Nektar Therapeutics a Hold rating. The average price target is $2.75, which means analysts expect the stock to gain by 304.41% over the next twelve months. That average ranking earns Nektar Therapeutics an Analyst Rating of 3, which is better than 3% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NKTR a Hold today. Find out what this means to you and get the rest of the rankings on NKTR!